Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 503797, 5 pages
http://dx.doi.org/10.1155/2008/503797
Review Article

The Critical Role of PPAR in Human Malignant Melanoma

1Department of Oral and Maxillofacial Plastic Surgery, Tübingen University Hospital, Osianderstrasse 2-8, 72076 Tübingen, Germany
2Department of Anatomy II: Experimental Morphology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany

Received 28 February 2008; Accepted 21 April 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Christian Freudlsperger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Wolchok and P. O. Livingston, “Vaccines for melanoma: translating basic immunology into new therapies,” Lancet Oncology, vol. 2, no. 4, pp. 205–211, 2001. View at Publisher · View at Google Scholar
  2. L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, “Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview,” Journal of Experimental and Clinical Cancer Research, vol. 19, no. 1, pp. 21–34, 2000. View at Google Scholar
  3. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar
  4. M. J. Garnett and R. Marais, “Guilty as charged: B-RAF is a human oncogene,” Cancer Cell, vol. 6, no. 4, pp. 313–319, 2004. View at Publisher · View at Google Scholar
  5. J. Luo, B. D. Manning, and L. C. Cantley, “Targeting the PI3K-Akt pathway in human cancer: rationale and promise,” Cancer Cell, vol. 4, no. 4, pp. 257–262, 2003. View at Publisher · View at Google Scholar
  6. L. Simpson and R. Parsons, “PTEN: life as a tumor suppressor,” Experimental Cell Research, vol. 264, no. 1, pp. 29–41, 2001. View at Publisher · View at Google Scholar
  7. H. Tsao, X. Zhang, K. Fowlkes, and F. G. Haluska, “Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines,” Cancer Research, vol. 60, no. 7, pp. 1800–1804, 2000. View at Google Scholar
  8. S. Huang, A. DeGuzman, C. D. Bucana, and I. J. Fidler, “Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice,” Clinical Cancer Research, vol. 6, no. 6, pp. 2573–2581, 2000. View at Google Scholar
  9. K. I. Amiri, L. W. Horton, B. J. LaFleur, J. A. Sosman, and A. Richmond, “Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma,” Cancer Research, vol. 64, no. 14, pp. 4912–4918, 2004. View at Publisher · View at Google Scholar
  10. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar
  11. R. Mukherjee, L. Jow, D. Noonan, and D. P. McDonnell, “Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators,” Journal of Steroid Biochemistry and Molecular Biology, vol. 51, no. 3-4, pp. 157–166, 1994. View at Publisher · View at Google Scholar
  12. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
  13. T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Review of Cell and Developmental Biology, vol. 12, pp. 335–363, 1996. View at Publisher · View at Google Scholar
  14. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
  15. T. Kubota, K. Koshizuka, E. A. Williamson et al., “Ligand for peroxisome proliferator-activated receptor ? (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,” Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998. View at Google Scholar
  16. E. Elstner, C. Müller, K. Koshizuka et al., “Ligands for peroxisome proliferator-activated receptor? and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998. View at Publisher · View at Google Scholar
  17. P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through PPAR?,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998. View at Publisher · View at Google Scholar
  18. Y. Tsubouchi, H. Sano, Y. Kawahito et al., “Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-? agonists through induction of apoptosis,” Biochemical and Biophysical Research Communications, vol. 270, no. 2, pp. 400–405, 2000. View at Publisher · View at Google Scholar
  19. H. Sato, S. Ishihara, K. Kawashima et al., “Expression of peroxisome proliferator-activated receptor (PPAR)? in gastric cancer and inhibitory effects of PPAR? agonists,” British Journal of Cancer, vol. 83, no. 10, pp. 1394–1400, 2000. View at Publisher · View at Google Scholar
  20. W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells,” Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000. View at Google Scholar
  21. Y.-F. Guan, Y.-H. Zhang, R. M. Breyer, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death,” Neoplasia, vol. 1, no. 4, pp. 330–339, 1999. View at Publisher · View at Google Scholar
  22. M. Rivier, I. Safonova, P. Lebrun, C. E. M. Griffiths, G. Ailhaud, and S. Michel, “Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes,” Journal of Investigative Dermatology, vol. 111, no. 6, pp. 1116–1121, 1998. View at Publisher · View at Google Scholar
  23. M. Westergaard, J. Henningsen, M. L. Svendsen et al., “Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid,” Journal of Investigative Dermatology, vol. 116, no. 5, pp. 702–712, 2001. View at Google Scholar
  24. H. Y. Kang, E. Chung, M. Lee, Y. Cho, and W. H. Kang, “Expression and function of peroxisome proliferator-activated receptors in human melanocytes,” British Journal of Dermatology, vol. 150, no. 3, pp. 462–468, 2004. View at Publisher · View at Google Scholar
  25. H. Y. Kang, J. Y. Lee, J. S. Lee, and Y. M. Choi, “Peroxisome proliferator-activated receptors-γ activator, ciglitazone, inhibits human melanocyte growth through induction of apoptosis,” Archives of Dermatological Research, vol. 297, no. 10, pp. 472–476, 2006. View at Publisher · View at Google Scholar
  26. J. S. Lee, Y. M. Choi, and H. Y. Kang, “PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes,” Experimental Dermatology, vol. 16, no. 2, pp. 118–123, 2007. View at Publisher · View at Google Scholar
  27. L. L. Eastham, C. N. Mills, and R. M. Niles, “PPARα/γ expression and activity in mouse and human melanocytes and melanoma cells,” Pharmaceutical Research, vol. 25, no. 6, pp. 1327–1333, 2008. View at Publisher · View at Google Scholar
  28. C. Freudlsperger, I. Moll, U. Schumacher, and A. Thies, “Anti-proliferative effect of peroxisome proliferator-activated receptor γ agonists on human malignant melanoma cells in vitro,” Anti-Cancer Drugs, vol. 17, no. 3, pp. 325–332, 2006. View at Publisher · View at Google Scholar
  29. R. Mössner, U. Schulz, U. Krüger et al., “Agonists of peroxisome proliferator-activated receptor ? inhibit cell growth in malignant melanoma,” Journal of Investigative Dermatology, vol. 119, no. 3, pp. 576–582, 2002. View at Publisher · View at Google Scholar
  30. W. Placha, D. Gil, A. Dembińska-Kieć, and P. Laidler, “The effect of PPARγ ligands on the proliferation and apoptosis of human melanoma cells,” Melanoma Research, vol. 13, no. 5, pp. 447–456, 2003. View at Publisher · View at Google Scholar
  31. N. P. Núñez, H. Liu, and G. G. Meadows, “PPAR-γ ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells,” Cancer Letters, vol. 236, no. 1, pp. 133–141, 2006. View at Publisher · View at Google Scholar
  32. H. Okano, K. Shiraki, H. Inoue et al., “15-deoxy-?12,14-PGJ2 regulates apoptosis induction and nuclear factor-?B activation via a peroxisome proliferator-activated receptor-?-independent mechanism in hepatocellular carcinoma,” Laboratory Investigation, vol. 83, no. 10, pp. 1529–1539, 2003. View at Publisher · View at Google Scholar
  33. D. S. Straus, G. Pascual, M. Li et al., “15-deoxy-?12,14-prostaglandin J2 inhibits multiple steps in the NF-?B signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4844–4849, 2000. View at Publisher · View at Google Scholar
  34. C. Freudlsperger, A. Thies, U. Pfüller, and U. Schumacher, “The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-γ agonist rosiglitazone in human melanoma cells,” Anticancer Research, vol. 27, no. 1A, pp. 207–213, 2007. View at Google Scholar
  35. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006. View at Publisher · View at Google Scholar
  36. E. Atallah and L. Flaherty, “Treatment of metastatic malignant melanoma,” Current Treatment Options in Oncology, vol. 6, no. 3, pp. 185–193, 2005. View at Publisher · View at Google Scholar
  37. M. Seimandi, G. Lemaire, A. Pillon et al., “Differential responses of PPARa, PPARd , and PPAR? reporter cell lines to selective PPAR synthetic ligands,” Analytical Biochemistry, vol. 344, no. 1, pp. 8–15, 2005. View at Publisher · View at Google Scholar
  38. C. E. Clay, A. M. Namen, G.-I. Atsumi et al., “Magnitude of peroxisome proliferator-activated receptor-? activation is associated with important and seemingly opposite biological responses in breast cancer cells,” Journal of Investigative Medicine, vol. 49, no. 5, pp. 413–420, 2001. View at Publisher · View at Google Scholar
  39. E. Lucarelli, L. Sangiorgi, V. Maini et al., “Troglitazione affects survival of human osteosarcoma cells,” International Journal of Cancer, vol. 98, no. 3, pp. 344–351, 2002. View at Publisher · View at Google Scholar